# A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

> **NCT07503873** · PHASE2 · NOT_YET_RECRUITING · sponsor: **TG Therapeutics, Inc.** · enrollment: 350 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ublituximab
- **DRUG:** Ublituximab
- **DEVICE:** AI Device

## Key facts

- **NCT ID:** NCT07503873
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-21
- **Primary completion:** 2027-07-31
- **Final completion:** 2029-05-30
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07503873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07503873, "A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT07503873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*